Nasdaq:ABVC
ABVC BIOPHARMA, INC.
A pre-revenue biotech firm focused on proprietary small molecule therapeutics, currently operating with significant cash burn and minimal commercial revenue streams.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the potential of the underlying drug candidates to gain approval and generate substantial future royalties or sales, potentially turning the current losses into significant returns upon successful commercialization; the strong balance sheet with $13.3M in equity and $681k in cash provides a runway to continue R&D efforts despite recent revenue declines.
Bear Case
The company exhibits classic characteristics of a distressed biotech firm with consistent net losses widening from -$5.3M in 2024 to -$8.4M in 2025, coupled with negligible revenue that has trended downward over the last five years; high operating expenses relative to minimal gross profit and a growing retained earnings deficit of nearly $77M suggest an unsustainable business model without immediate funding or breakthrough product milestones.
About ABVC BIOPHARMA, INC.
ABVC Biopharma Inc. is a biotechnology company focused on developing novel therapeutics, primarily operating within the small-molecule drug discovery space to address unmet medical needs in oncology and other areas. The company generates limited revenue from product sales and licensing while sustaining operations through equity financing and strategic partnerships in the competitive pharmaceutical sector.
Analysis
Management Discussion
Recent financial performance highlights a deepening net loss of $8.4M in 2025 compared to a revenue contraction from $1.0M in 2022 to $0.3M, indicating substantial operational challenges in generating commercial traction; while cash flow from financing remains positive at $4.6M, the operating cash flow deficit of $3.0M and negative net profit suggest the company is burning through its cash reserves without achieving sustainable profitability.
Industry Overview
The biotechnology industry is characterized by high-risk, high-reward dynamics where companies invest heavily in research and development with the hope of generating blockbuster drugs that can offset years of losses; success depends on navigating complex regulatory pathways and securing strategic partnerships to bring novel therapeutics to patients facing unmet medical needs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $969.8K | $152.4K | $509.6K | $296.0K |
| Cost of Revenue | $286.4K | $302.0K | $763 | $0 |
| Gross Profit | $683.4K | $-149.6K | $508.8K | $296.0K |
| Operating Expenses | $15.8M | $8.1M | $5.2M | $7.4M |
| Operating Income | $-15.1M | $-8.2M | $-4.7M | $-7.2M |
| R&D | $2.7M | $1.1M | $179.3K | $121.1K |
| G&A | $6.1M | $5.4M | $2.3M | $2.9M |
| Stock-Based Comp | $7.0M | $1.6M | $2.8M | $4.1M |
| D&A | $23.8K | — | — | — |
| Depreciation | $23.8K | $28.5K | $32.0K | $25.3K |
| Other OpEx | $7.0M | $1.6M | $2.8M | $4.4M |
| Non-Operating Income | $-400.2K | $-2.4M | $-664.3K | $-1.2M |
| Interest Expense | $294.0K | $2.5M | — | — |
| Interest Income | $187.8K | $185.5K | $87.4K | $167.1K |
| Pre-Tax Income | $-15.5M | $-10.7M | $-5.4M | $-8.4M |
| Income Tax | $797.8K | $256.0K | $-110.5K | $24.2K |
| Continuing Ops | $-16.3M | $-10.9M | $-5.3M | $-8.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-16.3M | $-10.9M | $-5.3M | $-8.4M |
| Minority Interest | $110.9K | $-394.6K | $-356.2K | $-468.4K |
| Net to Common | $-16.4M | $-10.5M | $-4.9M | $-7.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.0M | $1.7M | $2.2M | $2.5M |
| Cash & Equivalents | $85.3K | $60.2K | $248.4K | $681.5K |
| Marketable Securities | $75.8K | $79.3K | $64.7K | $64.4K |
| Accounts Receivable | $98.3K | $1.5K | — | — |
| Prepaid Expenses | $150.2K | $101.1K | $96.2K | $346.6K |
| Other Current Assets | $2.6M | $1.4M | $1.8M | $1.4M |
| Long-Term Assets | $6.9M | $12.8M | $5.4M | $18.6M |
| PP&E (Net) | $574.0K | $8.0M | $511.1K | $12.8M |
| Operating Leases | $1.2M | $809.3K | $640.4K | $1.9M |
| LT Investments | $842.1K | $2.5M | $2.3M | $1.9M |
| Other LT Assets | $3.4M | $-998.2K | $2.3M | $2.1M |
| Total Assets | $9.9M | $14.5M | $7.5M | $21.1M |
| Current Liabilities | $5.8M | $5.9M | $6.6M | $6.2M |
| Current Leases | $369.3K | $401.8K | $403.6K | $317.6K |
| Deferred Revenue | — | $79.5K | $81.1K | $12.6K |
| Other Current Liab | $2.5M | $1.8M | $6.1M | $5.8M |
| Long-Term Liabilities | $799.8K | $429.1K | $258.5K | $1.6M |
| LT Operating Leases | $791.8K | $407.5K | $236.8K | $1.6M |
| Other LT Liab | $8.0K | $21.7K | $-274.3K | $0 |
| Total Liabilities | $6.6M | $6.4M | $6.8M | $7.8M |
| Shareholders' Equity | $3.2M | $8.1M | $724.0K | $13.3M |
| Paid-In Capital | $67.9M | $82.6M | $78.6M | $96.0M |
| Retained Earnings | $-54.9M | $-65.4M | $-68.9M | $-76.9M |
| AOCI | — | $516.4K | $445.7K | $487.6K |
| Treasury Stock | $9.1M | $8.9M | $8.9M | $8.9M |
| Total L&E | $9.9M | $14.5M | $7.5M | $21.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-16.3M | $-10.9M | $-5.3M | $-8.4M |
| Non-Cash Adjustments | $5.4M | $6.7M | $3.3M | $5.6M |
| Working Capital Changes | $3.5M | $-406 | $153.6K | $-176.1K |
| Cash from Operations | $-7.4M | $-4.2M | $-1.8M | $-3.0M |
| Capital Expenditures | $119.7K | $21.2K | — | — |
| Cash from Investing | $-1.7M | $-360.2K | $0 | $-1.2M |
| Cash from Financing | $4.0M | $3.9M | $2.0M | $4.6M |
| FX Effect | $-67.3K | $2.1K | $-24.6K | $20.3K |
| Net Change in Cash | $-5.2M | $-674.9K | $147.0K | $463.2K |
| Beginning Cash | $6.6M | $1.4M | $716.8K | $863.8K |
| Ending Cash | $1.4M | $716.8K | $863.8K | $1.3M |
Frequently Asked Questions
How does ABVC BIOPHARMA, INC. make money?
The company's financial profile indicates a single primary segment focused on research and development of novel therapeutics, supplemented by minor licensing revenue and interest income from marketable securities, with no distinct commercial sales divisions evident in the current reporting period.
What are the main risks for ABVC?
Significant cash burn exceeding $8M annually with minimal revenue generation creates high dilution risk for shareholders; the company faces potential regulatory hurdles in bringing new drugs to market without commercial sales history; reliance on equity financing exposes investors to ongoing dilution and volatile share price dynamics.
What is ABVC's competitive advantage?
The company possesses a proprietary pipeline of novel small molecule drugs targeting specific disease mechanisms, access to specialized biotechnology talent, and a strategic capital structure supported by substantial paid-in capital designed to fund long-term clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.